Page 11 - Onxeo Sa Euronext News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Onxeo sa euronext. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Onxeo Sa Euronext Today - Breaking & Trending Today

Onxeo S.A.: Onxeo Reports Its 2021 Half-Yearly Financial Results and Provides an Update on Its Activities

Onxeo S.A.: Onxeo Reports Its 2021 Half-Yearly Financial Results and Provides an Update on Its Activities
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , France General , Walter Thomas Hofstaetter , Nicolas Merigeau , Julien Miara , Jean Pierre Bizzari , Acrotech Biopharma , Judith Greciet , Emmanuel Huynh , Shefali Agarwal , Onxeo Sa Euronext , Valerie Leroy , Gustave Roussy , Institut Curie , American Association For Cancer Research , Scientific Advisory Committee , Company Group , Euronext Growth Paris , Nasdaq First North , Chief Executive Officer , State Guaranteed , General Meeting , European Fight Kids Cancer , European Innovative Therapies , Oncology Cancer Case Reports , American Association ,

Onxeo S.A.: Onxeo: Report on the Combined General Meeting of June 10, 2021

Onxeo S.A.: Onxeo: Report on the Combined General Meeting of June 10, 2021
Shefali Agarwal, MD, a clinical development expert in oncology, is appointed Director of Onxeo
Regulatory News:
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, announced that the Combined General Meeting held today in camera adopted all the resolutions presented, in accordance with the recommendations of the Board of Directors.
The shareholders of the Company also renewed for three years the mandate of Mr. Thomas Hofstaetter, which expired at the end of this General Meeting and ratified the appointment of Mr. Julien Miara, representing Invus, to replace Mr. Jean-Pierre Kinet until the expiry of his mandate, at the end of the Meeting called to approve the accounts for the year ended December 31, 2021. ....

United States , France General , Jean Pierre Kinet , Nicolas Merigeau , Julien Miara , Emmanuel Huynh , Shefali Agarwal , Valerie Leroy , Onxeo Sa Euronext , Gustave Roussy , Thomas Hofstaetter , Institut Curie , Company Group , Clinical Development , Euronext Growth Paris , Nasdaq First North , Combined General Meeting , General Meeting , Executive Vice President , Chief Medical , Clinical Development Officer , General Meetings , Euronext Paris , Inhibitor Administered Intravenously , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் ,

Onxeo Receives Notice of Allowance for a New Patent

Onxeo S.A.
Onxeo” or “
the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA™, its first-in-class inhibitor of tumor DNA repair, in combination with any PARP inhibitor (PARPi). This patent protects both the combination of AsiDNA™ with a PARPi and its use for the treatment of certain cancers for which the DNA repair pathway via homologous recombination (HR) is not impaired or deficient. These so-called HR-proficient tumors are significantly less sensitive to treatment with PARP inhibitors. ....

United States , France General , Nicolas Merigeau , Onxeo Sa Euronext , Valerie Leroy , Judith Greciet , Emmanuel Huynh , Brian Ritchie , Trademark Office , Euronext Paris , Notice Allowance , Chief Executive Officer , Inhibitor Administered Intravenously , Nasdaq First , Englj Med , European Medical Oncology , Paris Stock Exchange Onxeo Pa , Nxeo Sa , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , வலேரி லெராய் , இம்மானுவேல் ஹூய்னி , பிரையன் ரிச்சி , முத்திரை அலுவலகம் , தலைமை நிர்வாகி அதிகாரி , நாஸ்டாக் முதல் ,

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA in Combination With a PARP Inhibitor in the United States

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA in Combination With a PARP Inhibitor in the United States
Regulatory News:
Onxeo or
the Company , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA, its first- in-class inhibitor of tumor DNA repair, in combination with any PARP inhibitor (PARPi). This patent protects both the combination of AsiDNA with a PARPi and its use for the treatment of certain cancers for which the DNA repair pathway via homologous recombination (HR) is not impaired or deficient. These so-called HR-proficient tumors are significantly less sensitive to treatment with PARP inhibitors. ....

United States , France General , Nicolas Merigeau , Onxeo Sa Euronext , Valerie Leroy , Judith Greciet , Emmanuel Huynh , Brian Ritchie , Trademark Office , Euronext Paris , Notice Allowance , Chief Executive Officer , Inhibitor Administered Intravenously , Englj Med , European Medical Oncology , Relations Strategic Communication , Sci Advisors , Nasdaq First North , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , வலேரி லெராய் , இம்மானுவேல் ஹூய்னி , பிரையன் ரிச்சி , முத்திரை அலுவலகம் , தலைமை நிர்வாகி அதிகாரி , ஐரோப்பிய மருத்துவ புற்றுநோயியல் ,

Onxeo S.A.: Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of Onxeo's current and future programs Regulatory News: Onxeo ....

United States , France General , United Kingdom , Nicolas Merigeau , Gilbert Chu , Ruth Plummer , Judith Greciet , Emmanuel Huynh , Lorenzo Galluzzi , Gilles Favre , Onxeo Sa Euronext , Valerie Leroy , Gustave Roussy , Caroline Robert , Institut Curie , Newcastle Experimental Cancer Medicine Centre , Parisv University , Newcastle University , Northern Institute For Cancer Research , Toulouse Research Center , Genetic Oncology Laboratory Medicine , Company Group , Newcastle Cancer Centre , Stanford Medical School , Princeton University , Harvard Medical School ,